Shares of Coloplast A/S (OTCMKTS:CLPBY – Get Rating) have been assigned a consensus recommendation of “Hold” from the seven research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $920.00.
Several research firms recently commented on CLPBY. Barclays decreased their price target on shares of Coloplast A/S from 835.00 to 815.00 and set an “underweight” rating on the stock in a research note on Tuesday, January 10th. Sanford C. Bernstein began coverage on shares of Coloplast A/S in a research report on Tuesday. They set a “market perform” rating for the company.
Coloplast A/S Trading Up 1.7 %
CLPBY stock opened at $11.50 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.90 and a current ratio of 1.29. The company’s 50-day simple moving average is $11.92 and its 200 day simple moving average is $11.54. Coloplast A/S has a 52 week low of $9.58 and a 52 week high of $16.00. The company has a market capitalization of $24.84 billion, a PE ratio of 41.07 and a beta of 0.28.
Coloplast A/S Company Profile
Coloplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Interventional Urology segment covers the sale of urological products, including disposable products.
- Get a free copy of the StockNews.com research report on Coloplast A/S (CLPBY)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ’s Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.